Mutual Advisors LLC Raises Stake in Novo Nordisk A/S $NVO

Key Points

• Mutual Advisors LLC increased its stake in Novo Nordisk A/S by 19.7%, owning 45,318 shares valued at approximately $3.25 million as of the end of the second quarter.
• Several institutional investors modified their positions in Novo Nordisk A/S, with Copeland Capital Management raising its holdings by 184.8% during the first quarter.
• Analysts have given Novo Nordisk A/S a consensus rating of "Moderate Buy", with two "Strong Buy" ratings and one "Sell" rating amid recent upgrades and downgrades by various firms.

Mutual Advisors LLC lifted its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 19.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 45,318 shares of the company's stock after buying an additional 7,469 shares during the quarter. Mutual Advisors LLC's holdings in Novo Nordisk A/S were worth $3,249,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Copeland Capital Management LLC grew its holdings in shares of Novo Nordisk A/S by 184.8% during the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after buying an additional 255 shares in the last quarter. North Capital Inc. purchased a new stake in Novo Nordisk A/S in the first quarter valued at approximately $27,000. Stone House Investment Management LLC purchased a new stake in Novo Nordisk A/S in the first quarter valued at approximately $30,000. Disciplina Capital Management LLC grew its holdings in Novo Nordisk A/S by 162.3% in the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company's stock valued at $33,000 after purchasing an additional 297 shares during the period. Finally, Spirit of America Management Corp NY purchased a new stake in Novo Nordisk A/S in the first quarter valued at approximately $35,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Price Performance

NVO opened at $56.72 on Thursday. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 52-week low of $45.05 and a 52-week high of $119.07. The company has a 50 day moving average of $56.03 and a two-hundred day moving average of $62.94. The company has a market cap of $253.23 billion, a P/E ratio of 15.58, a P/E/G ratio of 2.60 and a beta of 0.68.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The company had revenue of $11.69 billion during the quarter, compared to the consensus estimate of $77.51 billion. On average, analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were paid a dividend of $0.4119 per share. This represents a yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S's payout ratio is currently 22.53%.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Wall Street Zen downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Rothschild & Co Redburn upgraded shares of Novo Nordisk A/S from a "neutral" rating to a "buy" rating in a report on Tuesday, September 16th. UBS Group downgraded shares of Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a report on Tuesday, August 5th. Berenberg Bank upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Wednesday, September 17th. Finally, Morgan Stanley downgraded shares of Novo Nordisk A/S from an "overweight" rating to an "underweight" rating and lowered their target price for the company from $59.00 to $47.00 in a report on Monday, September 29th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $76.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.